Palo Alto Investors LP Relmada Therapeutics, Inc. Transaction History
Palo Alto Investors LP
- $501 Million
- Q1 2025
A detailed history of Palo Alto Investors LP transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Palo Alto Investors LP holds 495,146 shares of RLMD stock, worth $311,941. This represents 0.03% of its overall portfolio holdings.
Number of Shares
495,146
Previous 495,146
-0.0%
Holding current value
$311,941
Previous $257,000
48.25%
% of portfolio
0.03%
Previous 0.04%
Shares
3 transactions
Others Institutions Holding RLMD
# of Institutions
49Shares Held
6.3MCall Options Held
0Put Options Held
0-
Acadian Asset Management LLC Boston, MA1.23MShares$773,5940.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.21MShares$761,0870.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$361,1870.0% of portfolio
-
Geode Capital Management, LLC Boston, MA302KShares$190,1860.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny288KShares$181,4400.0% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $18M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...